Document is current
Any future updates will be listed below
-
Authors
Schwartz, Carolyn E. https://orcid.org/0000-0002-9173-7774
Stark, Roland B.
Borowiec, Katrina
Nolte, Sandra
Myren, Karl-Johan
-
Funding
Funding for this research was provided by:
alexion pharmaceuticals
- License Information
-
More Information
Article History
Received: 14 June 2021
Accepted: 24 August 2021
First Online: 15 September 2021
Declarations
:
: The trial was approved by the institutional review board at each participating institution. All trial procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All trial patients provided written informed consent for use of their data in primary and secondary analyses related to quality of life studies. For the EORTC general-population data, ethical approval was not sought as this study was solely based on panel research data collected by GfK SE. The survey conformed to the required ethical standards by obtaining written informed consent from all participants and collecting data completely anonymously.
: Not applicable.
: Dr. Schwartz and Mr. Stark are employees of DeltaQuest Foundation, which received research funding for the work reported herein. Dr. Nolte declares no potential conflicts of interest and reports no disclosures. Mr. Myren is an employee of Alexion Pharmaceuticals which developed the drugs being evaluated.
